Table 3. Correlation of treatment options with tumour control and overall survival.
| Total | Tumour control at 4–7months | Survival (No./%) | |||
| Therapy combinations | No./% | No Lesion | Residual | Alive | Dead |
| 1. EBRT alone | 78(37.3) | 65 (40.1) | 13 (27.7) | 49 (62.8) | 29 (37.2) |
| 1+ External boost | 47(22.5) | 28 (17.3) | 19 (40.4) | 24 (51.0) | 23 (49.0) |
| 1+ Brachy | 18(8.6) | 15 (9.3) | 3 (6.4) | 14 (77.8) | 4 (22.2) |
| 1+ chemo | 52(24.9) | 41(28.3) | 11 (23.4) | 45 (86.5) | 7 (13.5) |
| 1+ brachy + chemo | 14(6.7) | 13 (8.0) | 1 (2.1) | 13 (92.8) | 1 (7.1) |
| Total/ p-value | 209(100) | p<0.014 | p<0.001 | ||
Most patients received only the initial EBRT (37.8%), while 24.9% and 8.6% got additional chemotherapy and brachytherapy respectively. Only 6.7% of patients received combined treatment of EBRT, brachytherapy and chemotherapy. The kind of treatment options the patient received seemed to significantly affect tumour response and overall patient survival as shown here. On adjusting for age and HIV status through multivariate cox proportional hazards regression analysis and multinomial logistic regression, this statistical significance was maintained.